Hormones Reimagined: Why Menopause Therapy Is Safer Than You Think

County Obstetrics & Gynecology

STL Leaders in Women’s Healthcare

Call the Office 636 680-1960
Menu

Hormones Reimagined:

Why Menopause Hormone Replacement Therapy Is Safer Than You Think

Updated Evidence from Long-Term Follow-Up (20-Year Data)

Key Message:
“Women in early menopause with bothersome symptoms should not be afraid to take hormone therapy,”  

  • Estradiol therapy used for over 10 years was found to be safe for the breast.
  • Modern hormone therapy reduced the breast cancer mortality rate by up to 50%, and this benefit was seen across all age groups, lowering the risk of dying from breast cancer.
  • Modern hormone therapy reduced the risk of coronary heart disease by up to 50%, and this benefit was seen across all age groups, lowering the risk of dying from cardiovascular disease by over 30%.

Hormone Reolacement therapy is safe for women who:

    • Are younger and closer to the time of menopause
    • Use bioidentical hormones (e.g., estradiol and micronized progesterone)

Analysis revealed that most of the risks were:

    • Were in older women, far past menopause, that had never used hormone therapy before

Follow-up studies published in JAMA and other major journals show that:

For healthy women under 60 or within 10 years of menopause

…benefits outweigh risks when HT is used for symptom relief.

Here are the findings from the long-term follow-up:

Breast Cancer Risk and Menopausal Hormone Therapy

Estrogen Alone (CEE)

    • 20–45% reduction in both breast cancer incidence and mortality among women taking estrogen-only therapy.
    • This protective effect persisted even 18 years after treatment ended.

Estrogen + Progestin (MPA)

    • The WHI trial using CEE (conjugated equine estrogens) plus MPA (Prempro) showed a slight increase in breast cancer incidence compared to placebo.
    • The risk was small in absolute terms, roughly equivalent to that associated with drinking one to two alcoholic beverages per day.

Why the Early Data Misled:

    • The controversy stemmed from comparing against a placebo group with artificially low cancer rates.
      • Placebo group included many women (25%) who had recently discontinued HT, this group showed an unusually low cancer rates, distorting comparisons.

The Progesterone makes a difference:

At the time the Women’s Health Initiative (WHI) began in the 1990s, the only form of progesterone available for use in combination therapy was medroxyprogesterone acetate (MPA), a synthetic progestin.

    • Medroxyprogesterone acetate (MPA) is not a true progesterone—it differs structurally and biologically from the natural hormone produced by the ovaries.
    • This distinction is critical because MPA retains certain adverse metabolic and vascular effects that natural progesterone does not. These may have contributed to the increased risks reported in the early WHI findings.

Bioidentical Hormones

Modern Understanding and Safer Alternatives

  • Modern formulations use micronized (bioidentical) progesterone which is chemically identical to the progesterone naturally produced by the human body and has a neutral or even protective effect on breast tissue and cardiovascular health.
  • Studies show that bioidentical progesterone does not increase breast cancer risk and may offset some of the pro-inflammatory and pro-thrombotic effects seen with older synthetic progestins.
  • This change in formulation—moving from MPA to bioidentical progesterone—represents one of the most important advances in the safety and tolerability of modern hormone therapy.

Cardiovascular Risk and Menopausal Hormone Therapy

Why Estradiol Helps the Heart

  • Improves cholesterol profiles (↑ HDL, ↓ LDL)
  • Anti-inflammatory and antiplatelet effects
  • Enhances blood vessel flexibility (vasodilation)
  • Reduces plaque buildup and arterial stiffness

Timing Matters: “The Timing Hypothesis”

Starting HT before age 60 or within 10 years of menopause is associated with:

  • ↓ 50% in coronary heart disease
  • ↓ 30–48% in overall mortality
  • ↓ rates of heart attack and heart failure
  • No increase in stroke, blood clots, or cancer

Benefits continued 6 years after stopping HT.

Late Initiation

  • Women starting HT after age 60 or >10 years post-menopause do not experience the same cardiovascular benefits and may face higher clot risk.

Modern Hormone Therapy Options

Bioidentical Estradiol and Micronized Progesterone better mimic natural hormones.

Non-oral delivery (patch, gel, or pellet) preferred for cardiovascular and clot safety.

  • The advantage of a transdermal estrogen is that it is not metabolized by the liver. And because it’s not metabolized by the liver, we don’t see that increase in blood clots.

You deserve accurate information and individualized care—not outdated fear.

At County Obstetrics & Gynecology, menopause care is provided exclusively by board-certified physicians. 

Our providers offer personalized hormone therapy to help you navigate menopause. 

We can assess your hormonal needs, recommend supportive lifestyle adjustments, and create a personalized hormone replacement therapy plan to help you feel your best.

What Hormones are right for Me?

If you’re experiencing symptoms of menopause—or simply have questions—we welcome you to call our office for a consultation.

THE HISTORY

1940s–1980s: Early Use and Popularity

  • 1940s–50s: Estrogen (e.g., Premarin) begins widespread use to treat menopausal symptoms.
  • Hormones began to gain traction in the 1960s as a way to preserve youthfulness and femininity.
    • 1966: Dr. Robert Wilson publishes Feminine Forever, promoting estrogen therapy as a way to remain youthful.
  • 1975: Studies show increased risk of endometrial cancer with unopposed estrogen.
    • Leads to the addition of progestin in HRT for women with a uterus.
  • In the 1980’s, Hormone therapy gained popularity again, shown to relieve hot flashes, night sweats, vaginal dryness, and help maintain bone density. Early studies suggested cardiovascular benefits.
  • Several observational studies found that women taking hormone therapy had less heart disease and bone fractures and less risk of death from all causes, compared with women who were not taking them.

1991: Launch of the WHI Study

  • The National Institutes of Health (NIH) initiates the Women’s Health Initiative, a long-term national health study of postmenopausal women.
    • Goals: Investigate major causes of death and disability in women, including cancer, cardiovascular disease, and osteoporosis.
  • Nearly 15 million women were getting annual prescriptions for hormone therapy.
  • In 2002 results of a major women’s health study (WHI Study) challenged the safety of menopause hormones, and overnight, millions of women and their doctors abandoned the drugs.

This abrupt reversal left countless Baby Boomer and Gen X women to struggle through challenging menopausal symptoms—such as hot flashes, night sweats, insomnia, and mood changes—without access to the highly effective relief that hormone therapy had previously been thought to provide.

Overview of the WHI Hormone Study

  • Study Design
    • The Women’s Health Initiative (WHI), launched in the 1990s, enrolled over 160,000 postmenopausal women to evaluate the long-term effects of hormone therapy (HT).
    • Two main interventions were tested:
      • Estrogen + Progestin (Prempro): for women with a uterus.
      • Estrogen-only (CEE): for women after hysterectomy.

Impact of the 2002 Findings

The study was abruptly stopped in 2002 after early reports linked HT to higher risks of breast cancer, heart disease, stroke, and blood clots.

    • This caused panic and led millions to stop treatment, despite previous beliefs that hormones were both symptom-relieving and heart-protective.
    • Overnight, millions of women discontinued HT, and physicians became reluctant to prescribe it.

2004: Estrogen Alone Arm Stopped

  • March 2004: Trial halted due to:
    • Increased stroke risk.
    • No overall benefit for heart disease prevention.

No increase in breast cancer, unlike the combined arm.

2007–2013: Reanalysis and Age-Stratified Insights

  • Emerging data suggest timing matters:
    • Women who start HRT closer to menopause (ages 50–59) have fewer risks and more benefits than older women.

Led to more nuanced “timing hypothesis”: HRT may be cardioprotective if started early, harmful if started late.

2017–2020: Position Statements and Shifting Guidelines

  • NAMS (North American Menopause Society), ACOG, and Endocrine Society revise guidelines:
    • HRT is appropriate for healthy women <60 or within 10 years of menopause with bothersome symptoms.
    • Emphasis on individualized risk–benefit assessment.

Key Limitations of the Original WHI

    • Age Bias
      • Most participants were over 60 and well past menopause — not representative of women typically starting HT.
    • Hormone Type
      • The study used conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA), a synthetic progestin.
      • MPA is not a true progesterone. It differs chemically and biologically from the body’s natural hormone and retains potentially harmful metabolic and vascular effects.
      • At that time, bioidentical progesterone was not yet available for clinical use in the United States.
      • The type of progestin used (medroxyprogesterone acetate) is now known to increase breast cancer risk.
    • Flawed Comparison
      • The placebo group included women who had recently discontinued hormone therapy—skewing breast cancer results by artificially lowering their risk and falsely higher risk in the treatment group.

County Obstetrics & Gynecology

STL Leaders in Women’s Healthcare

Call the Office 636 680-1960

Board Certified Physician:

Dr. Lawrence V. Boveri

Dr. Stephen A. Boveri

Our Location

1859 Bowles Avenue

Suite 103

Fenton, MO 63026

Our Hours:

Monday:              9:00 – 5:00

Tuesday:             9:00 – 5:00

Wednesday:       9:00 – 5:00

Thursday:           9:00 – 3:00

Friday:                 9:00 – 12:00